Skip to content
Clinical ResearchResearch compoundLimited evidence

Usmarapride

Experimental drug candidate for Alzheimer's disease; improved memory in animals, only early safety studies in humans.

NootropicSerotonergicMemoryCholinergicAcetylcholineSerotoninBDNF

Pharmacology

ClassMemory · Cholinergic
Primary target5-HT4 receptor partial agonism
Targets4 receptor targets
Half-lifeNot clearly reported in public literature (characterized in Phase 1 PK studies)
OnsetProfiled for once-daily oral dosing (no human efficacy data)
EvidenceLimited evidence
Affected systemsAcetylcholineSerotoninBDNF

Contents

DETAILED OVERVIEW

What is Usmarapride?

Usmarapride (development code SUVN-D4010) is an experimental drug candidate being developed for the memory and thinking problems that come with Alzheimer's disease. It is not approved anywhere, it is not a dietary supplement, and it is not freely available.

It partly switches on one of the serotonin receptors. In animal studies this released more acetylcholine (a messenger important for learning and remembering) in the cortex, improved memory and showed a protective effect on nerve cells. In humans it has only reached the first phase of clinical trials, which measured safety and how the body handles the drug; there are no human data on whether it works. Headache was seen in the early studies, and nausea and bowel complaints are also possible because they are a known effect of this drug group. Long-term safety is unknown, and safety in pregnancy and breastfeeding has not been established.

Mechanism

5-HT4 partial agonist (cholinergic + sAPP-alpha)

Evidence

Preclinical + Phase 1 human PK/safety

Legal status

Unapproved clinical-stage candidate

Receptor profile

  • 5-HT4 receptorsStrong
  • Cortical acetylcholine releaseModerate
  • Non-amyloidogenic sAPP-alpha processingModerate
  • Hippocampal BDNF / neurogenesisModerate

Safety

Side effects, stop signs, contraindications

Side effects · 5

  • Headache, also noted in early human testing
  • Nausea and other gastrointestinal effects, a known class effect of 5-HT4 agonists
  • Theoretical prokinetic gut effect of 5-HT4 agonists (diarrhea, abdominal cramping)
  • Limited long-term human safety data: reached only Phase 1 trials
  • Not an approved medicine; long-term tolerability unknown

Contraindications · 4

  • Pregnancy and breastfeeding: safety not established, avoid
  • Pre-existing cardiac arrhythmia: older 5-HT4 agonists warrant cardiac caution (though usmarapride is more selective)
  • Active gastrointestinal disease where increased motility could be problematic
  • Unapproved investigational clinical-stage compound; not recommended without medical supervision

Related Nootropics

Same therapeutic category

Studies

Related research and clinical findings

FAQ

FAQ

Usmarapride is an experimental drug candidate from Alzheimer's disease research, designed to help with memory problems and slow nerve cell damage. In animal models it improved memory and learning and showed nerve-protective effects, but it has only reached early clinical testing (Phase 1), meaning there is very little human data and it is not an established, readily available substance.

Telegram

Have a question about Usmarapride?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeNootropic
FormulaC21H29N5O2
UpdatedOctober 13, 2026
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 13, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.